- Bristol-Myers (BMY) Squibb's melanoma drug ipilimumab.
- Corcept Therapeutics' (CORT) Corlux in Cushing's syndrome.
- Seattle Genetics' (SGEN) brentuximab vedotin in anaplastic large cell lymphoma.
- Cyclacel Pharmaceuticals' (CYCC) seliciclib in non-small cell lung cancer.
BOSTON ( TheStreet) -- The October biotech calendar is chock-full of potentially stock moving events, including a dozen drugs facing U.S. approval decisions. Phase III or pivotal studies that could report results in October: